MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$1.07
Change
-$0.03 (-2.73%)
Capitalization
87.21M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IMAB with price predictions
Jan 14, 2025

Momentum Indicator for IMAB turns positive, indicating new upward trend

IMAB saw its Momentum Indicator move above the 0 level on January 03, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where IMAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMAB just turned positive on January 03, 2025. Looking at past instances where IMAB's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

IMAB moved above its 50-day moving average on January 08, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

IMAB broke above its upper Bollinger Band on January 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). IMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (26.667) is also within normal values, averaging (263.573).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IMAB is expected to report earnings to rise 16.27% to -12 cents per share on November 29

I-MAB IMAB Stock Earnings Reports
Q3'23
Est.
$-0.13
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
Q1'24
Est.
$-0.22
Q4'23
Beat
by $0.36
The last earnings report on November 14 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 366.76K shares outstanding, the current market capitalization sits at 87.21M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

IMAB and Stocks

Correlation & Price change

A.I.dvisor tells us that IMAB and CTMX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMAB and CTMX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
-2.73%
CTMX - IMAB
32%
Poorly correlated
-0.84%
RPRX - IMAB
31%
Poorly correlated
-0.65%
SANA - IMAB
27%
Poorly correlated
-2.77%
AVTE - IMAB
27%
Poorly correlated
+6.17%
LGND - IMAB
27%
Poorly correlated
+0.73%
More